Purpose: To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC). Methods: Prospective, double-blind, randomized placebo-controlled study. Nineteen eyes of 17 patients with persistent subretinal fluid (SRF) due to CSC were enrolled and randomized to receive eplerenone 50 mg/day or placebo for 3 months, followed by a 3-month follow-up. The main outcome measure was change in SRF from baseline to 3 months of treatment. Secondary outcomes included change in SRF at any time-point, complete resolution of SRF, improvement in choroidal thickness and change in best-corrected visual acuity (BCVA). Results: Thirteen eyes were treated with eplerenone and six with placebo. Both groups showed reduction in SRF throughout the treatment period, with a significant reduction at months 1, 3 and 5 only in the treatment group. Twentythree per cent in the treatment group and 30.8% per cent in the placebo group experienced complete resolution of SRF. A significant improvement in BCVA was noted in the placebo group at 4 months, as well as a significant difference in BCVA between groups at 3 months in favour of the placebo group (p = 0.005). There was no significant difference in choroidal thickness in either group throughout the study period. No adverse events related to eplerenone were noted in the treatment group. Conclusion: In this study, eplerenone was not found to be superior to placebo in eyes with chronic CSC.
Introduction
Central serous chorioretinopathy (CSC) is a condition characterized by the development of serous detachment of the neurosensory retina (Bouzas et al. 2002; Gemenetzi et al. 2010; Carvalho-Recchia et al. 2012) . The detachment results from altered barriers and insufficient pumping function at the level of the retinal pigment epithelium (RPE), although the main pathology may involve the chorio-capillaries (Carvalho-Recchia et al. 2002 Gemenetzi et al. 2010) . The incidence of the disease is approximately 1:10 000, and it mostly affects young adult men (Kitzmann et al. 2008; Wang et al. 2008) . Central serous chorioretinopathy (CSC) may be either acute or chronic, with the chronic form defined as more than 3 months' duration to more than 6 months, according to different authors (Liegl & Ulbig 2014) .
The role of corticosteroids in the development of CSC has been well documented, both for exogenous treatment and their endogenous production, and it has been linked to both glucocorticoid and mineralocorticoid dysfunction (Harada & Harada 1985; Yannuzzi 1987; Bouzas et al. 1993; Garg et al. 1997; Tittl et al. 1999; Carvalho-Recchia et al. 2002; Haimovici et al. 2003 Haimovici et al. , 2004 Jonas & Kamppeter 2005) . Preclinical studies have shown that the glucocorticoid receptor, mineralocorticoid receptor and hydroxysteroid dehydrogenase type 2 (HSD-2) are co-expressed in the retina and choroid (Zhao et al. 2010 (Zhao et al. , 2012 . It was shown that mineralocorticoid receptors within the choroidal vessels of rat eyes caused choroidal vasodilation and leakage when activated and that the resultant choroidal thickening was inhibited in the presence of mineralocorticoid receptor antagonism (Zhao et al. 2012) .
Eplerenone (Inspra; Pfizer, Inc., New York, NY, USA) is a mineralocorticoidspecific receptor antagonist that is commercially available and US Food and Drug Administration (FDA)-approved for various systemic diseases, including hypertension and congestive heart failure.
Several studies described the use of mineralocorticoid antagonists for CSC in humans (Bousquet et al., 2015; Breukink et al. 2014; Herold et al. 2014; Maier et al. 2014; Chin et al. 2015; Ghadiali et al. 2015; Ryan & Pulido 2015; Salz et al. 2015; Singh et al. 2015) . Most of them were retrospective studies. Three prospective studies have been published to date. Two investigated the mineralocorticoid antagonist spironolactone (Aldactone, Pfizer, Inc., New York, NY, USA): one was a 3-month long, nonrandomized prospective study (Herold et al. 2014) . The other was a randomized, controlled, study, examining the efficacy of spironolactone for 67 days in a crossover trial (Bousquet et al. 2015) . Only one prospective study investigated eplerenone. It was a nonrandomized study with 3 months of follow-up (Bousquet et al. 2013 ). Our study is the first randomized, double-blind, placebocontrolled study, in which we evaluated the efficacy of eplerenone in patients with chronic CSC.
Materials and Methods

Study population
Patients included in this study were diagnosed with CSC based on clinical examination, fluorescein angiography (FA) and optical coherence tomography (OCT). Eligibility criteria included: (i) patients aged 18-65; (ii) decreased vision due to CSC; (iii) OCT finding of chronicity, defined as persistent subretinal fluid SRF involving the foveal centre of more than 4-months duration; (iv) evidence of leakage caused by CSC on FA.
Exclusion criteria included: (i) evidence of choroidal neovascularization (CNV); (ii) history of other macular diseases; (iii) diabetic patients with a history of microalbuminuria; (iv) history of uveitis; (v) ocular surgery within 3 months prior to study entry; (vi) systemic contraindication for eplerenone treatment: hyperkalemia >5 mmol/l, use of medications that inhibit the enzyme CYP3A4, serum creatinine >2 mg/dl for men or 1.8 ml/dl for women or creatinine clearance <50 ml/min, use of potassium additives or potassium-sparing diuretics, use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers; (vii) women who are pregnant, lactating or do not use oral contraceptive pills; (viii) known allergy to fluorescein. Patients previously treated with photodynamic therapy (PDT) or antivascular endothelial growth factor (anti-VEGF) intravitreal injections were not excluded from the study, provided that treatment was not given within 3 months of study entry.
Study design
This was a prospective, double-blind, randomized placebo-controlled study. Patients were enrolled in the study from August 2014 to May 2015. All consecutive patients with a diagnosis of chronic CSC from the retina clinic at the Tel Aviv Medical Center who met the inclusion criteria and consented were enrolled in the study. Chronic CSC was defined as persistent SRF involving the foveal centre without signs of resolution on OCT for 4 months. Candidates were followed up bimonthly during that time, and only patients without signs of improvement in SRF on OCT were included in the study. Although indocyanine green (ICG) angiography may be used in the diagnosis of CSC, it was not used in the diagnosis in this study, as the demographic data, history, clinical examination and OCT and FA, as assessed by retina specialists, did not raise suspicion of a different disease entity.
Ethics
The study was approved by the Tel Aviv Medical Center ethics committee and was conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study was declared on clinicaltrials.gov Identifier under # NCT02153125 (May 29, 2014) .
Study drug
Tablets containing either eplerenone or placebo (comprised of dextrose) were prepared by the hospital pharmacist and were dispensed to the participants by the investigators, who were masked to the drug. Tablets had identical galenic presentation.
Study protocol
Subjects were randomized 2:1 for treatment with eplerenone or placebo. Randomization to either group was assigned by the pharmacist. The labels providing the batch number were placed by the pharmacist and were in line with the ministry of health directive number 14.
All patients in the treatment group received eplerenone at a dose of 25 mg/ day for 1 week, followed by 50 mg/day for 11 weeks if no serum electrolyte or blood pressure abnormalities were encountered. The total treatment period was thus 3 months. The same protocol was followed for patients in the placebo group, with placebo medications marked as 25 mg or 50 mg. All subjects were then followed up for additional 3 months after cessation of the treatment.
Examinations
Examination and follow-up protocol are shown in Fig. 1 and Table 1 . At baseline, all patients underwent a complete ophthalmological examination, including BCVA and spectral domain OCT (SD-OCT). Medical examination, as detailed in Table 1 , was performed, and all subjects were examined by an internal medicine specialist (A.N.) to assess for medical conditions or medications that would exclude them from entering the study. Subjects were instructed to avoid consuming grapefruit juice throughout the treatment period, which could interfere with the enzyme CYP3A4.
Subjects that fit the inclusion criteria were given 25 mg eplerenone or placebo per day for 1 week, followed by an assessment for treatment tolerance as detailed in Table 1 and an OCT examination. If they were found to be tolerant, subjects were given 50 mg medication per day for another week, followed by another treatment tolerance assessment. Those that were tolerant continued the treatment for a total of 3 months from baseline, with monthly follow-up visits at the end of each month (months 1-3). After 3 months, treatment was stopped and patients returned for monthly followup visits for three additional months (months 4-6).
Patients were to be excluded from the study in the case of intolerable side-effects from the treatment (e.g. heart palpitations, gynaecomastia, gastrointestinal side-effects); hyperkalemia (>5 mmol/l); hyponatremia (<132 mmol/l); worsening renal function; hypotension; or if significant deterioration was seen on OCT, FA or BCVA during the study period.
Optical coherence tomography acquisition and analysis
All participants were examined through dilated pupils using Heidelberg Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany). The retinas of both eyes were first scanned by a horizontal high-speed raster scanning protocol of a 20°9 20°quadrangular area, and central macular thickness (CMT) was obtained after ensuring correct segmentation and centralization.
Subretinal fluid (SRF) was measured from the raster that showed the maximal SRF at the fovea by one of the investigators (S.C.), with an SD-OCT software electronic calliper. The calliper was placed from above the RPE to the inner part of the outer segment of the photoreceptors. The measurements were later verified by two additional investigators (D.G., Z.H.W.).
In addition, to demonstrate choroidal thickness changes, EDI technique was used (Spaide et al. 2008; Margolis & Spaide 2009 ). The choroid was scanned with 20°horizontal and vertical single cross-sectional enhanced depth imaging (EDI) scans through the centre of the fovea. To ensure high quality and noise reduction, the eye tracking system and averaging technique were employed. Each choroidal scan consisted of 100 averaged OCT frames. Images were converted to white on black greyscale to sharpen the contrast and allow a more accurate measurement. Choroidal thickness was measured by one investigator (S.C.), with an SD-OCT software electronic calliper, and was later verified by two additional investigators (D.G., Z.H.W). Choroidal thickness was defined as the vertical distance between the outer margin of the hyperreflective RPE layer and the chorioscleral interface. Choroidal thickness was measured at the location of maximal SRF, as chosen during SRF measurement. An average of two measurements was taken -one from the horizontal and the other from the vertical cross section.
The follow-up acquisition mode was used in all follow-up visits and automatically placed follow-up scans in precisely the same anatomic location as previous scans. All measurements were depicted at the exact same place at all follow-up examinations.
Main outcome measures
The primary outcome measure was the change in SRF from baseline after 3 months of treatment. This was measured at the apex of the subretinal detachment as described above using the Spectralis SD-OCT device.
Secondary outcome measures included change in SRF at any timepoint until the 6 months' follow-up complete resolution of SRF as measured using the Spectralis SD-OCT device (defined as the absence of SRF in all OCT sections); improvement in choroidal thickness as measured by enhanced depth imaging Spectralis SD-OCT; and change in BCVA compared to baseline. The equivalent logarithm of the minimum angle of resolution acuity (logMAR) was calculated and used for analysis.
Statistical analysis
Data were summarized descriptively. Categorical data were described as numbers and percentages, and continuous variables as mean and standard deviation or median. In nonmetric parameters, statistical differences between medication group and placebo were found using Fisher's exact test. Metric variables were compared using the Mann-Whitney nonparametric test. Differences between times were compared by Wilcoxon nonparametric test. Spearman nonparametric correlation was performed between changes in SRF and other continuous variables. p < 0.05 was considered statistically significant.
The power calculation was based on the treatment period of this study (i.e. baseline to month 3). To have 80% power of detecting a reduction in SRF of 40% (at a statistically significant level of a = 5%) between baseline SRF and SRF at 3 months, 12 eyes are required in the treatment group and six in the placebo group.
All statistical analyses were carried out with SPSS version 23 (IBM, Armonk, NY, USA).
Results
Patient baseline characteristics
Twenty eyes of 18 patients met the inclusion criteria of the study. One patient had an early exit from the study after reporting gastrointestinal sideeffects and palpitations within a few days of commencing treatment. On unmasking, it was found that she was treated with the placebo drug.
Therefore, 19 eyes of 17 patients were included in the data analysis. The treatment group included 13 eyes of 12 patients, and the control group consisted of six eyes of five patients.
Baseline characteristics are shown in Table 2 . One patient in the treatment group and two in the placebo group had bilateral disease. Of the two cases with bilateral disease in the placebo group, three eyes met the inclusion criteria. Eight (66.7%) patients in the treatment group and four (80%) in the placebo group were males (p = 1.00). The mean age was 50.6 AE 8.1 years (range, 33-60 years) in the treatment group and 47.2 AE 13.79 years (range, 35-65 years) in the placebo group (p = 0.72). The mean duration of CSC was 3.1 AE 2.1 years in the treatment group and 2.2 AE 1.04 years in the placebo group (p = 0.56). Three patients in the treatment group (23%) and two in the placebo group (33.3%) reported previous intake of corticosteroids (p = 1.00).
Six (46.1%) participants in the treatment group were previously treated for CSC. Four were treated with anti-VEGF (despite lack of evidence of CNV clinically or on imaging), of those two with ranibizumab and four with bevacizumab, without signs of improvement; two were treated previously with rifampin and three with PDT. One patient in the placebo group reported previous treatment with bevacizumab and rifampin (p = 0.333). There was no difference between the treatment and placebo groups in regard to baseline characteristics.
One patient in the treatment group suffered from severe chronic disease, which included cystoid macular oedema (CME) in both eyes. Only one eye had SRF in addition to the CME, and this eye was chosen as the study eye.
Follow-up data
One patient in the treatment group was lost to follow-up after 3 months of treatment. Another patient in the treatment group (mentioned previously as having a severe chronic disease with CME) was exempted from the study after 5 months due to substantial worsening in CME. Two patients in the treatment group missed their 1-week follow-up, one by a week and another by 2 weeks. This follow-up was nevertheless regarded as the 1-week followup. The change in SRF over time is shown in Fig. 2 . The treatment group showed a decrease in SRF that was seen as early as 1 week post-treatment initiation with 25 mg/day eplerenone and continued until the 3-month visit, after which there was a gradual mean increase in SRF. There was a statistically significant difference between the baseline amount of SRF and SRF measurements at 1, 3 and 5 months (p = 0.015, 0.006, 0.021, respectively).
In the placebo group, there was also a decrease in SRF, which lasted until the 4-month visit. However, no statistically significant difference from baseline was found in SRF measurements during the study period for this group.
To evaluate the treatment effect of eplerenone, we compared the mean difference in SRF during the two study periods (the treatment period in the first 3 months in comparison with the follow-up period in the last 3 months) between the two groups. The mean change in SRF in the treatment period was À74.9 lm in the eplerenone group and À100.3 lm in the placebo group, without a statistically significant difference (p = 0.74). The mean change in SRF in the follow-up period was 33 lm in the eplerenone group and 8.3 in the placebo group, with no significant difference (p = 0.1).
Three eyes in the treatment group (23%) had complete resolution of SRF at month 3, vs. two eyes (33.3%) in the placebo group (p = 1.00). However, four (30.8%) of thirteen eyes in the treatment group did not experience a noticeable change in SRF, while one patient experienced improvement only at month 5. When evaluating factors that differ between responders and nonresponders, disease duration was found to be longer in nonresponders (4.5 years vs. 2.3 years in responders, p = 0.03). There was no statistically significant difference in age, sex or past treatment between responders and nonresponders. Figure 3 shows the change in CMT over time. A statistically significant difference between CMT at baseline and 3 months (p = 0.008) was found in the treatment group and between CMT at baseline and 4 months (p = 0.046) in the placebo group. There was no statistically significant difference in CMT at any time-point between groups. Figure 4 shows the change in choroidal thickness over time. In the treatment group, thickness changed in a seesaw pattern. There was no statistically significant difference between baseline and any time-point. In the placebo group, there was no statistically significant difference between baseline and any timepoint. There was no statistically significant difference in choroidal thickness at any time-point between groups.
Visual acuity
The treatment group showed no statistically significant difference between baseline BCVA and the BCVA at each time-point (0.6 AE 0.8 baseline, 0.5 AE 0.57 at 1 month, 0.48 AE 0.52 at 2 months, 0.38 AE 0.5 at 3 months, 0.43 AE 0.53 at 4 months, 0.66 AE 0.8 at 5 months, 0.48 AE 0.55 at 6 months). In the placebo group, there was a statistically significant improvement in BCVA only at the 4-month visit (0.2 AE 0.24 at baseline, 0.21 AE 0.57 at 1 month, 0.27 AE 0.25 at 2 months, 0.01 AE 0.02 at 3 months, 0.16 AE 0.27 at 4 months, 0.22 AE 0.25 at 5 months, 0.27 AE 0.27 at 6 months). When comparing each timepoint between groups, mean BCVA was statistically better in the placebo group compared to the treatment group at 3 months (0.01 AE 0.02 vs. 0.38 AE 0.5, p = 0.005). There was no difference in BCVA between the groups at all other time-points.
The relative change in BCVA over time is presented in Fig. 5 .
Measures of correlation
We investigated possible correlations among patients treated with eplerenone between the change in SRF from baseline to 3 months and each of the study variables. In a univariate analysis, there was no correlation between SRF change and the patient's age, BCVA, CMT or choroidal thickness at baseline. However, there was a negative correlation between duration of disease before the study and change in SRF, wherein patients with a longer duration had less change in SRF during the treatment period (r = À0.771, p = 0.005; Fig. 6 ).
Safety
None of the patients in the treatment group complained of side-effects during the treatment period. No abnormalities in electrolytes, ECG or blood pressure were found during the treatment period. One patient in the treatment group had elevated creatine phosphokinase (CPK) levels of 7000 fifty-one days after study commencement, which occurred a day after performing strenuous exercise at the gym. After treatment with IV fluids, CPK levels were normalized. He was examined by an internist at the emergency department, and the elevation in CPK was attributed to exercise and not the treatment drug.
Discussion
The results of our study suggest that eplerenone is not superior to placebo in eyes with chronic CSC. Subretinal fluid (SRF) improved in both the treatment and the placebo group, although significantly only in the former, while visual acuity improved significantly only in the placebo group. This is the first prospective randomized controlled trial conducted on chronic CSC patients to compare the efficacy of eplerenone vs. placebo. In addition, it has the longest treatment and follow-up period among prospective studies that used mineralocorticoid receptor antagonists for the treatment of CSC.
The primary outcome of this study was the amount of reduction in SRF during the treatment period. In the treatment group, a statistically significant decrease in SRF in comparison with baseline was seen at months 1, 3 and 5. The amount of SRF was less at the 6-month follow-up compared to baseline (143.3 AE 48.9 lm vs. 101.7 AE 74.8 lm, respectively), though not statistically significant. In the placebo group, a decrease in SRF was also noted during the 3-months treatment period, as well as a month later. However, the change was not found to be statistically significant, which may be explained by the small size of this group.
It is noteworthy that the reduction in SRF in the treatment group was consistent throughout the treatment period and mostly worsened after treatment was stopped, while in the placebo group, the reduction in SRF lasted until month 4. This may suggest a stronger correlation between the study drug and SRF improvement, as opposed to spontaneous improvement, which took place in the placebo group. This is also demonstrated in CMT measurements, where a significant reduction was seen at 3 months in the treatment group and at 4 months in the placebo group, as CMT is a manifestation of the amount of SRF. Also of note is the statistical result for CMT change, which was very significant in the treatment group between baseline and 3 months (p = 0.008), in comparison with a less significant result in the placebo group at 4 months (p = 0.046), which also may point more at chance (probably related to spontaneous resolution) rather than a true difference.
Four subjects in the treatment group (30.8%) did not experience a noticeable change in SRF. This is in line with previous data. In a retrospective study by Daruich et al. (2016) describing the use of oral mineralocorticoids in patients with nonresolving CSC, 18 of 54 eyes (33.3%) did not show a change in SRF from baseline during 6 months of treatment and thus were termed nonresponders.
Our study examined several secondary outcomes: complete resolution of SRF, change in BCVA and change in choroidal thickness. Complete resolution of SRF was observed in three patients in the treatment group (23%), in comparison with two in the placebo group (33.3%). In contrast, in their study on the treatment of patients with chronic CSC with eplerenone, Bousquet et al. (2013) demonstrated a higher proportion of eyes with complete resolution of SRF: three of 12 patients (25%) underwent complete resolution of SRF after 1 month, and six of the rest (67%) underwent complete resolution at 3 months. However, that study did not include a control group. Spontaneous improvement of SRF is not uncommon in CSC patients. Such improvement was also seen in the crossover study using spironolactone for chronic CSC, where two eyes in the placebo group experienced a substantial reduction in SRF before crossing-over to spironolactone treatment (Bousquet et al. 2015) .
There was no statistically significant difference in choroidal thickness at any time-point within each of the groups or between groups, similar to a retrospective study by Ghadiali et al. (2015) , conducted on 23 eyes of 14 patients treated by Yannuzzi, where no significant change in choroidal thickness was seen at any follow-up point during 12 months of treatment. These results are in contrast to the crossover study by Bousquet et al. (2015) , who found a significant difference in choroidal thickness between the treated group and the placebo group (treatment effect vs. period effect), and the retrospective study by Daruich et al. (2016) , which showed such difference at 1, 3 and 5 months after starting treatment with mineralocorticoid receptor antagonists.
We found a trend, although not statistically significant, for improvement in BCVA in the treatment group from baseline to 3 months, with decline after treatment cessation at most timepoints. A similar trend was seen in the placebo group, with no significant improvement throughout the 3 months of treatment. However, at 4 months, the improvement became significant. This is in line with the improvement in SRF, which lasted 4 months in the placebo group. When comparing the visual improvement at 3 months between the groups, it was significantly in favour of the placebo group.
It is worth noting that at most timepoints, no significant change in BCVA was seen, either from baseline or between groups. This is in line with findings in other studies. In the crossover study by Bousquet et al. (2015) although there was a change in BCVA, it was not statistically significant. In the retrospective real-life study by Daruich et al. (2016) in which patients were treated with mineralocorticoid receptor antagonists for up to 12 months, a significant change in BCVA from baseline was only seen after 6 months of treatment, suggesting that a longer treatment period may have resulted in better BCVA outcomes.
In our study, univariate analysis showed a negative correlation between disease duration prior to the study and change in SRF. Patients with a longer duration demonstrated less change in SRF during the treatment period (r = À0.771). We also found a statistically significant difference between responders and nonresponders to eplerenone in disease duration. These findings suggests that early treatment may be considered once a patient's chronic status is established (after three to 6 months (Liegl & Ulbig 2014) ), as delaying treatment may result in reduced efficacy and consequently less reduction of SRF. Further research should be conducted to compare the rate of response between patients with early and late disease chronicity.
Seven of the participants in the study have been previously treated for CSC, either with anti-VEGF agents, with rifampin or with PDT. Typically, anti-VEGF therapy is not expected to provide benefit in cases of CSC that are not complicated by active CNV. Indeed, none of the subjects in our study had shown sign of an active CNV in the past. However, when faced with chronic CSC with visual acuity deterioration, that is nonresponsive to other treatments, some clinicians attempt this treatment modality. While no largescale prospective trials have been published, the literature contains multiple studies regarding the use of anti-VEGF for the treatment of chronic CSC (Bae et al. 2011; Semeraro et al. 2012; Pitcher et al. 2015) .
Three of the participants in our study have been previously treated with PDT. The use of this treatment modality has not been shown to decrease the efficacy of other treatments, including mineralocorticoid antagonists. Moreover, in real-life reviews on the use of mineralocorticoid antagonists published recently, a significant percentage of subjects had been treated with PDT prior to inclusion in the study (Daruich et al. 2016; Ghadiali et al. 2016 ). We did not find a statistically significant difference between responders and nonresponders to the drug in relation to previous treatment.
We found a good safety profile for eplerenone. While some studies used spironolactone, a different mineralocorticoid receptor antagonist, (Herold et al. 2014; Bousquet et al. 2015; Ghadiali et al. 2015; Ryan & Pulido 2015) it may cause unwanted progestational and anti-androgenic side-effects, including gynaecomastia, abnormal menstrual cycles and impotence, which may limit its use. Due to its different structure, eplerenone has a lower affinity for other steroid receptors, and therefore a better safety profile (Delyani 2000) . None of the patients in this study demonstrated any of the drug's side-effects. One patient who experienced gastrointestinal side-effects and palpitations was treated with the placebo drug. Another patient experienced CPK elevation at one point during the study, but the elevation was attributed to intense physical exercise performed the previous day, and improved after treatment with intravenous fluids.
This study has several limitations. First, the small sample size. Second, not all subjects were treatment na€ ıve. However, previous publications did not show any impact of previous treatments on the response to mineralocorticoid antagonists, and we did not find a significant difference between responders and nonresponders in relation to previous treatments in our study. In addition, we chose only patients who have not been treated for 3 months before commencing eplerenone treatment. Third, the course of CSC is known to be variable with spontaneous improvements in SRF. However, a correlation between change in SRF and BCVA and treatment period, as was demonstrated above, suggests a possible response to the study drug.
In conclusion, while this study showed a significant reduction in SRF during treatment with eplerenone, a trend for reduction was seen in the placebo group, possibly related to its smaller size. There was no difference in the treatment effect between the groups. A significant improvement in visual acuity was noted only in the placebo group. Based on these results, it seems that there is no benefit for eplerenone over placebo in the treatment of chronic CSC. We believe that the importance of this study is in it being a randomized, prospective, controlled study with a longer treatment and follow-up periods compared to previous studies. However, the study population is relatively small and the group of patients is heterogenous. Larger prospective, controlled studies are needed.
